Indinavir
Nervous system symptoms: in clinical controlled trials, frequently reported undesirable effects in patients receiving 600 mg efavirenz with other antiretroviral agents included, but were not limited to: dizziness, insomnia, somnolence, impaired concentration and abnormal dreaming. Nervous system symptoms of moderate-to-severe intensity were experienced by 19.4 % of patients compared to 9.0 % of patients receiving control regimens. These symptoms were severe in 2.0 % of patients receiving efavirenz 600 mg daily and in 1.3 % of patients receiving control regimens. In clinical studies 2.1 % of patients treated with 600 mg of efavirenz discontinued therapy because of nervous system symptoms. Nervous system symptoms usually begin during the first one or two days of therapy and generally resolve after the first 2 - 4 weeks. In one clinical study, the monthly prevalence of nervous system symptoms of at least moderate severity between weeks 4 and 48, ranged from 5 % - 9 % in patients treated with regimens containing efavirenz and 3 % - 5 % in patients treated with the control regimen. In a study of uninfected volunteers, a representative nervous system symptom had a median time to onset of 1 hour post-dose and a median duration of 3 hours. Nervous system symptoms may occur more frequently when efavirenz is taken concomitantly with meals possibly due to increased efavirenz plasma levels see section 5.2 ; . Dosing at bedtime seems to improve the tolerability of these symptoms and can be recommended during the first weeks of therapy and in patients who continue to experience these symptoms. Dose reduction or splitting the daily dose has not been shown to provide benefit. Analysis of long-term data from study 006 median follow-up 180 weeks, 102 weeks, and 76 weeks for patients treated with efavirenz + zidovudine + lamivudine, efavirenz + indinavir, and indinavir + zidovudine + lamivudine, respectively ; showed that, beyond 24 weeks of therapy, the incidences of new-onset nervous system symptoms among efavirenz-treated patients were generally similar to those in the control arm. Adverse reactions of moderate or greater severity with at least possible relationship to treatment regimen based on investigator attribution ; reported in clinical trials of efavirenz at the recommended dose in combination therapy n 1, 008 ; are listed. Clinical Psychopharmacology Section, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Department of Health and Human Services, Baltimore, Maryland R.B.R., M.H.B. Chemistry and Life Sciences Group, Research Triangle Institute International, Research Triangle Park, North Carolina B.E.B. Department of Psychiatry and Pharmacology, University of Mississippi Medical Center, Jackson, Mississippi W.L.W., K.G.A. Alcohol and Drug Abuse Research Center, Harvard Medical School, McLean Hospital, Belmont, Massachusetts S.S.N., N.K.M. and Departments of Biochemistry, Neurosciences, and Psychiatry, and the National Institutes of Mental Health Psychoactive Drug Screening Program, Case Western Reserve University School of Medicine, Cleveland, Ohio B.L.R.
Can indinavir affect human cells
Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278: 12951300. Grant, S. K., I. C. Deckman, M. D. Minnich, J. Culp, S. Franklin, G. B. Dreyer, T. A. Tomaszek, Jr., C. Debouck, and T. D. Meek. 1991. Purification and biochemical characterization of recombinant simian immunodeficiency virus protease and comparison to human immunodeficiency virus type 1 protease. Biochemistry 30: 84248434. Gulick, R. M., J. W. Mellors, D. Havlir, J. J. Eron, C. Gonzalez, D. McMahon, D. D. Richman, F. T. Valentine, L. Jonas, A. Meibohm, E. A. Emini, and J. A. Chodakewitz. 1997. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N. Engl. J. Med. 337: 734739. Hammer, S. M., K. E. Squires, M. D. Hughes, J. M. Grimes, L. M. Demeter, J. S. Currier, J. J. Eron, Jr., J. E. Feinberg, H. H. Balfour, Jr., L. R. Deyton, J. A. Chodakewitz, M. A. Fischl, et al. 1997. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N. Engl. J. Med. 337: 725733. Hartmann, K., A. Donath, B. Beer, H. F. Egberink, M. C. Horzinek, H. Lutz, G. Hoffmann-Fezer, I. Thum, and S. Thefeld. 1992. Use of two virustatica AZT, PMEA ; in the treatment of FIV and of FeLV seropositive cats with clinical symptoms. Vet. Immunol. Immunopathol. 35: 167175. Hayes, K. A., L. J. Lafrado, J. G. Erickson, J. M. Marr, and L. E. Mathes. 1993. Prophylactic ZDV therapy prevents early viremia and lymphocyte decline but not primary infection in feline immunodeficiency virus-inoculated cats. J. Acquir. Immune Defic. Syndr. 6: 127134. Higgins, J. R., N. C. Pedersen, and J. R. Carlson. 1986. Detection and differentiation by sandwich enzyme-linked immunosorbent assay of human T-cell lymphotropic virus type III lymphadenopathy-associated virus- and acquired immunodeficiency syndrome-associated retroviruslike clinical isolates. J. Clin. Microbiol. 24: 424430. Hirsch, M. S., B. Conway, R. T. D'Aquila, V. A. Johnson, F. Brun-Vezinet, B. Clotet, L. M. Demeter, S. M. Hammer, D. M. Jacobsen, D. R. Kuritzkes, C. Loveday, J. W. Mellors, S. Vella, and D. D. Richman. 1998. Antiretroviral drug resistance testing in adults with HIV infection implications for clinical management. J. Am. Chem. Soc. 279: 19841991. Ho, D. D. 1998. Toward HIV eradication or remission: the tasks ahead. Science 280: 18661867. Ho, D. D., A. U. Neumann, A. S. Perelson, W. Chen, J. M. Leonard, and M. Markowitz. 1995. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373: 123126. Hoog, S. S., E. M. Towler, B. Zhao, M. L. Doyle, C. Debouck, and S. S. Abdel-Meguid. 1996. Human immunodeficiency virus protease ligand specificity conferred by residues outside of the active site cavity. Biochemistry 35: 1027910286. Kuhmann, S. E., E. J. Platt, S. L. Kozak, and D. Kabat. 1997. Polymorphisms in the CCR5 genes of African green monkeys and mice implicate specific amino acids in infections by simian and human immunodeficiency viruses. J. Virol. 71: 86428656. Le Grand, R., B. Vaslin, J. Larghero, O. Neidez, H. Thiebot, P. Sellier, P. Clayette, N. Dereuddre-Bosquet, and D. Dormont. 2000. Post-exposure prophylaxis with highly active antiretroviral therapy could not protect macaques from infection with SIV HIV chimera. AIDS 14: 18641866. Li, T. S., R. Tubiana, C. Katlama, V. Calvez, H. Ait Mohand, and B. Autran. 1998. Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease. Lancet 351: 16821686. Luciw, P. A., E. Pratt-Lowe, K. E. S. Shaw, J. A. Levy, and C. Cheng-Mayer. 1995. Persistent infection of rhesus macaques with T-cell-line-tropic and macrophage-tropic clones of simian human immunodeficiency viruses SHIV ; . Proc. Natl. Acad. Sci. USA 92: 74907494. Martin, L. N., K. F. Soike, M. Murphey-Corb, R. P. Bohm, E. D. Roberts, T. J. Kakuk, S. Thaisrivongs, T. J. Vidmar, M. J. Ruwart, and S. R. Davio. 1994. Effects of U-75875, a peptidomimetic inhibitor of retroviral proteases, on simian immunodeficiency virus infection in rhesus monkeys. Antimicrob. Agents Chemother. 38: 12771283. McClure, H. M. 1990. Nonhuman primate models for evaluation of AIDS therapy. Ann. N. Y. Acad. Sci. 616: 287298. Miller, M., M. Jaskolski, J. K. Rao, J. Leis, and A. Wlodawer. 1989. Crystal structure of a retroviral protease proves relationship to aspartic protease family. Nature 337: 576579. Mitsuya, H., K. J. Weinhold, P. A. Furman, M. H. St. Clair, S. N. Lehrman, R. C. Gallo, D. Bolognesi, D. W. Barry, and S. Broder. 1985. 3 -Azido-3 deoxythymidine BW A509U ; : an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III lymphadenopathy-associated virus in vitro. Proc. Natl. Acad. Sci. USA 82: 70967100. Murry, J. P., J. Higgins, T. B. Matthews, V. Y. Huang, K. K. Van Rompay, N. C. Pedersen, and T. W. North. 2003. Reversion of the M184V mutation in simian immunodeficiency virus reverse transcriptase is selected by tenofovir, even in the presence of lamivudine. J. Virol. 77: 11201130. Perelson, A. S., P. Essunger, Y. Cao, M. Vesanen, A. Hurley, K. Saksela, M. The Medicines Control Agency has itself admitted to a ninety per cent underreporting of adverse reactions. 56 One of the issues which the ABPI wished to discuss with Ministers in the Task Force, was what they saw as the problem of NICE National Institute of Excellance ; . The ABPI pointed out that no other country in the world had a second tier of medicine and equipment evaluation after trials, which decided which were the best treatments. It would perhaps have worried them even more if NICE was a more transparent organization which also independently assessed the treatment value of complementary medicines! 57 Director of the &DQFHU 5HVHDUFK 8. Epidemiology Unit.
A prime example: the high blood pressure and congestive heart failure that results from the use of drugs used to lower cholesterol and aricept. Manufacturer Rescriptor is a potent NNRTI. Rescriptor is used in combination with other antiretrovirals and has been studied in both "protease-sparing" and "protease-containing" regimens. Rescriptor is an inhibitor of the cytochrome P450 enzyme system and therefore has the ability to raise blood levels of all four marketed protease inhibitors--saquinavir, indinavir, nelfinavir, and ritonavir--allowing for potential reduction of dosages e.g. reduce indinavir dose to 600 mg TID as per package insert ; . This ability to increase levels of all marketed protease inhibitors makes Rescriptor unique among the NNRTIs. Rescriptor is now available in 200 mg tablets, as well as the 100 mg tablets that can be easily dispersed in liquid avoid grapefruit juice ; and taking the drug as a slurry actually increases the bioavailablity by 20%. Rescriptor may be taken with or without food. Rescriptor should never be used as monotherapy, since resistance may develop rapidly. The most common side effect seen in patients using Rescriptor has been skin rash that usually lasts less than two weeks. --Agouron Pharmaceuticals. It is hoped that increasing education and awareness within resource-poor settings will help reduce the stigma and isolation often experienced by those with hiv aids, which frequently prevents people from accessing treatment even when freely available and trileptal. Pelton si, stanley k, yogev r, fletcher cv, mcintosh k, wiznia a, et al: pediatric aids clinical trials group 338 study team: switch from ritonavirto indinavir in combination therapy for hiv-1-infected children. Cross-Resistance to Other Antiviral Agents: Varying degrees of HIV-1 cross-resistance have been observed between indinavir and other HIV-1 protease inhibitors. In studies with ritonavir, saquinavir, and amprenavir, the extent and spectrum of cross-resistance varied with the specific mutational patterns observed. In general, the degree of cross-resistance increased with the accumulation of resistance-associated amino acid substitutions. Within a panel of 29 viral isolates from indinavir-treated patients that exhibited measurable 4-fold ; phenotypic resistance to indinavir, all were resistant to ritonavir. Of the indinavir resistant HIV-1 isolates, 63% showed resistance to saquinavir and 81% to amprenavir. CLINICAL PHARMACOLOGY Pharmacokinetics Absorption: Ind8navir was rapidly absorbed in the fasted state with a time to peak plasma concentration Tmax ; of 0.8 0.3 hours mean S.D. ; n 11 ; . greater than dose-proportional increase in indinavir plasma concentrations was observed over the 200-1000 mg dose range. At a dosing regimen of 800 mg every 8 hours, steady-state area under the plasma concentration time curve AUC ; was 30, 691 11, nMhour n 16 ; , peak plasma concentration Cmax ; was 12, 617 4037 nM n 16 ; , and plasma concentration eight hours post dose trough ; was 251 178 nM n 16 ; Effect of Food on Oral Absorption: Administration of indinavir with a meal high in calories, fat, and protein 784 kcal, 48.6 g fat, 31.3 g protein ; resulted in a 77% 8% reduction in AUC and an 84% 7% reduction in Cmax n 10 ; . Administration with lighter meals e.g., a meal of dry toast with jelly, apple juice, and coffee with skim milk and sugar or a meal of corn flakes, skim milk and sugar ; resulted in little or no change in AUC, Cmax or trough concentration. Distribution: Indjnavir was approximately 60% bound to human plasma proteins over a concentration range of 81 nM 16, 300 nM. Metabolism: Following a 400-mg dose of 14C-indinavir, 83 1% n 4 ; and 19 3% n 6 ; the total radioactivity was recovered in feces and urine, respectively; radioactivity due to parent drug in feces and urine was 19.1% and 9.4%, respectively. Seven metabolites have been identified, one glucuronide conjugate and six oxidative metabolites. In vitro studies indicate that cytochrome P-450 3A4 CYP3A4 ; is the major enzyme responsible for formation of the oxidative metabolites. Elimination: Less than 20% of indinavir is excreted unchanged in the urine. Mean urinary excretion of unchanged drug was 10.4 4.9% n 10 ; and 12.0 4.9% n 10 ; following a single 700-mg and 1000-mg dose, respectively. Indlnavir was rapidly eliminated with a half-life of 1.8 0.4 hours n 10 ; . Significant accumulation was not observed after multiple dosing at 800 mg every 8 hours. Special Populations Hepatic Insufficiency: Patients with mild to moderate hepatic insufficiency and clinical evidence of cirrhosis had evidence of decreased metabolism of indinavir resulting in approximately 60% higher mean AUC following a single 400-mg dose n 12 ; . The half-life of indinavir increased to 2.8 0.5 hours. Ind8navir pharmacokinetics have not been studied in patients with severe hepatic insufficiency see DOSAGE AND ADMINISTRATION, Hepatic Insufficiency ; . Renal Insufficiency: The pharmacokinetics of indinavir have not been studied in patients with renal insufficiency. Gender: The effect of gender on the pharmacokinetics of indinavir was evaluated in 10 HIV seropositive women who received CRIXIVAN 800 mg every 8 hours with zidovudine 200 mg every 8 hours and lamivudine 150 mg twice a day for one week. Indinnavir pharmacokinetic parameters in these women were compared to those in HIV seropositive men pooled historical control data ; . Differences in indinavir exposure, peak concentrations, and trough concentrations between males and females are shown in Table 1 below and antabuse. While indinavir in general should not be taken with 2 hours of a fattymeal, indinavir when taken in combination with low-dose ritonavir has norestrictions. Activist Its food restrictions and three times a day dosing make indinavir a tough drug to include in your regimen. Yet it's still one of the most powerful protease inhibitors. Combining indinavir with ritonavir leads to viral suppression comparable to that achieved when either drug is the only protease in a regimen. Better yet, the dual combination doesn't have food restrictions, it's dosed twice daily 400 mg of each ; , and it may reduce the risk of kidney stones, which Positively Aware January February 2000 and lariam!
Concomitant Antiretroviral Agents: Nelfinavir: The AUC and C max of nelfinavir 750 mg q8h ; are increased by 20% and 21%, respectively when given with SUSTIVA in uninfected volunteers. No dose adjustment is necessary when nelfinavir is administered in combination with SUSTIVA. Indinavir: When indinavir 800 mg every 8 hours ; was given with SUSTIVA 200 mg ; , the indinavir AUC and C max were decreased by approximately 31% and 16%, respectively as a result of enzyme induction. Therefore, the dose of indinavir should be increased from 800 mg to 1000 mg every 8 hours when SUSTIVA and indinavir are coadministered. No adjustment of the dose of SUSTIVA is necessary when given with indinavir. Ritonavir: When SUSTIVA and ritonavir 500 mg given every 12 hours ; were studied in uninfected volunteers, the AUC for each drug was increased by approximately 20%. The combination was associated with a higher frequency of adverse clinical experiences e.g., dizziness, nausea, paresthesia ; and laboratory abnormalities elevated liver enzymes ; . Monitoring of liver enzymes is recommended when SUSTIVA is used in combination with ritonavir. Saquinavir: When saquinavir soft gelatin capsules 1200 mg q8h ; were given with SUSTIVA to uninfected volunteers, saquinavir AUC and C max were decreased by 62% and 50%, respectively. Use of SUSTIVA in combination with saquinavir as the sole protease inhibitor is not recommended. Saquinavir Ritonavir: No pharmacokinetic data are available on the potential interactions of SUSTIVA with the combination of saquinavir and ritonavir. Amprenavir: SUSTIVA has the potential to decrease serum concentrations of amprenavir!
Attorney General's Sexual Assault Task Force Revised February 2005 93 Van Buren St., Eugene, OR 97402, Ph. 5412848275, Fax 5413430316, Email taskforce oregonsatf Page 3 of 18 and pletal. A practical preclinical model for the hyperbilirubinemia produced by human immunodeficiency virus protease inhibitors has been developed. Indinavir and atazanavir produced significant hyperbilirubinemia, whereas amprenavir, the negative control, was indistinguishable from the ritonavir booster dose. This model was used to disqualify an exploratory protease inhibitor from development. samples were drawn 4 hours after the final dose for serum bilirubin evaluation Zucker et al. used four doses of 240 mg kg three times a day ; . Unlike the previous report, in which a small 0.042 mg dl ; but significant increase from baseline was observed, bilirubin levels following the third dose of indinavir were not statistically significantly different than baseline mean change, 0.02 0.04 mg dl ; . We also administered atazanavir under similar conditions 100 mg kg BID ; and observed no change in bilirubin between baseline and day 2 4 h after the third dose ; . However, in an additional modification to the reported procedure, we also collected blood 4 hours following the initial dose of each of the above PIs. In contrast to the very small effects observed on day 2, five of six animals treated with indinavir experienced a bilirubin increase of 0.1 mg dl or greater, with one animal displaying an increase of 0.5 mg dl. Based on the above preliminary results, we repeated the above procedure three doses in a BID format ; , assessing serum bilirubin on day 0, prior to the initial dosing day, and 4 hours after both the first and third doses day 1 and day 2 ; . In attempt to optimize the plasma exposure of indinavir, which has a relatively short half-life in rats, we also boosted the indinavir pharmacokinetics by codosing with ritonavir 3 ; . All. HIV-infected individuals treated with protease inhibitors: the Swiss HIV cohort study. Circulation 1999; 100: 7005. Lo JC, Mulligan K, Tai VW, "Buffalo hump" in men with HIV-1 infection. Lancet 1998; 351: 86770. Saint-Marc T, Partisani M, Poizot-Martin I, et al. Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: preliminary results of the LIPOCO study. AIDS 2000; 14: 3749. Mallal SA, John M, Moore CB, et al. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS 2000; 14: 130916. Roth VR, Kravcik S, Angel JB. Development of cervical fat pads following therapy with human immunodeficiency virus type 1 protease inhibitors. Clin Infect Dis 1998; 27: 657. Miller KK, Daly PA, Sentochnik D, et al. Pseudo-Cushing's syndrome in human immunodeficiency virus-infected patients. Clin Infect Dis 1998; 27: 6872. Hengel RL, Watts NB, Lennox JL. Benign symmetric lipomatosis associated with protease inhibitors. Lancet 1997; 350: 1596. Safrin S, Grunfeld C. Fat distribution and metabolic changes in patients with HIV infection [editorial]. AIDS 1999; 13: 2493505. Carr A, Cooper DA. Adverse effects of antiretroviral therapy. Lancet 2000; 356: 142330. Henry K, Melroe H, Huebsch J, et al. Severe premature coronary artery disease with protease inhibitors [letter]. Lancet 1998; 351: 1328. Yeni PG, Hammer SM, Carpenter CCJ, et al. Antiretroviral treatment of adult HIV-1 infection in 2002: updated recommendations of the International AIDS Society-USA panel. JAMA 2002; 288: 22235. Perronne C, Bricaire F, Leport C. Hypoglycaemia and diabetes mellitus following parenteral pentamidine mesylate treatment in AIDS patients. Diabet Med 1990; 7: 5859. Henry K, Rathgaber S, Sullivan C. Diabetes mellitus induced by megestrol acetate in a patient with AIDS and cachexia. Ann Intern Med 1992; 116: 5354. Hadigan C, Meigs JB, Corcoran C, et al. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis 2001; 32: 1309. Mynarcik DC, McNurlan MA, Steigbigel RT. Association of severe insulin resistance with both loss of limb fat and elevated serum tumor necrosis factor receptor levels in HIV lipodystrophy. J Acquir Immune Defic Syndr 2000; 25: 31221. Noor MA, Lo JC, Mulligan K, et al. Metabolic effects of indinavir in healthy HIV-seronegative men. AIDS 2001; 15: F11F18. Despres JP, Lamarche B, Mauriege P, et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 1996; 334: 9527. Pyorala M, Miettinen H, Laakso M, et al. Hyperinsulinemia predicts coronary heart disease risk in healthy middle-aged men: the 22-year follow-up results of the Helsinki Policemen Study. Circulation 1998; 98: 398404. Meigs JB, Mittleman MA, Nathan DM, et al. Hyperinsulinemia, hyperglycemia, and impaired hemostasis: the Framingham Offspring Study. JAMA 2000; 283: 2218. Murata H, Hruz PW, Mueckler M. The mechanism of insulin resistance caused by HIV protease inhibitor therapy. J Biol Chem 2000; 275: 202514. Kosmiski LA, Kuritzkes DR, Lichtenstein KA, et al. Fat distribution and metabolic changes are strongly correlated and energy expenditure is increased in the HIV lipodystrophy syndrome. AIDS 2001; 15: 19932000. Caron M, Auclair M, Vigouroux C, et al. The HIV protease inhibitor indinavir impairs sterol regulatory element-binding protein-1 intranuclear localization, inhibits preadipocyte differentiation, and induces insulin resistance. Diabetes 2001; 50: 137888. Miserez AR, Muller PY, Spaniol V. Indinavir inhibits sterolregulatory element-binding protein-1c- dependent lipoprotein li and cyklokapron. Ciated with nevirapine resistance ; have been shown to restore susceptibility of HIV-1 to zidovudine, even in the presence of several resistance mutations previously selected by zidovudine16. The interpretation of information from genotypic assays benefits from expert opinion, although there are other more practical approaches see "Interpretation of Assays" ; . Several issues are still topics of research but will be mentioned here because of their future clinical relevance. While essential to understanding biology and epidemiology of resistant virus, the concepts of `primary' and `secondary' mutations are more applicable to clinical management of some drugs than others. Recently, the International AIDS Society USA Resistance Testing Consensus Panel has stopped differentiating between primary and secondary mutations for reverse transcriptase inhibitors see iasusa ; . This was intended to emphasize the generalization that a larger number of mutations including secondary mutations ; would be associated with higher levels of resistance and potential cross-resistance to both nucleoside RT inhibitors NRTI ; and nonnucleoside reverse transcriptase inhibitor NNRTI ; . In other words, secondary mutations cannot be ignored, or considered unimportant, by clinicians interpreting genotypic resistance tests. It now seems inadequate to rely only on primary mutations for identifying resistance. This concept has not yet been applied to protease inhibitors PI ; by the IAS-USA group. Management of some of the PIs, such as nelfinavir and saquinavir, can probably still be based on whether or not primary mutations are present, with less attention paid to secondary mutations. However, other protease inhibitors, such as indinavir or lopinavir, are better managed by attention to the total number of mutations present, as now suggested for reverse transcriptase inhibitors. Moreover, specific primary mutations are difficult to categorize for indinavir and lopinavir and need not be present for resistance to occur; an accumulation of secondary mutations may be all that is required for resistance. A second current research topic involves a special category of mutation that has been described in RT codon 215. Mutations that encode neither the wild type amino acid, threonine T ; , nor the resistant mutant amino acids, tyrosine Y ; or phenylalanine F ; can be seen at RT codon 215. Several studies show that RT 215 D, C, or S can be present in specimens from drug-nave persons in up to 10% of drug-nave subjects in some studies ; . These mutants have evolved by a single nucleotide change from the zidovudine resistant mutant allele RT 215 Y or F ; These mutations in codon 215 do not cause detectable decreased susceptibility to zidovudine in vitro, and confer better replicative capacity on the virus in the absence of drug than RT T215Y or F mutations17-21. In vitro data suggests more rapid selection of zidovudine resistant RT 215 Y or F from one of these special mutants than from the wild type22. This is presumably because the single nucleotide change to RT 215Y or F is more easily acquired from these special mutants than are the two nucleotide changes needed if.
Discount Indinavir online
Indinavir antiretroviral
In the first 15 years of the AIDS epidemic, individuals with HIV infection had few options for treatment of a disease that eventually destroyed their immune system and left them vulnerable to an early death from a variety of opportunistic infections and malignancies. Until the mid-to-late 1990s, when drug development in the US began to offer the prospect of significantly increased survival time and improved quality of life, AIDS patients could only write their last wills and testaments, say good bye to their loved ones, and hope to make the best of an appalling situation before they succumbed to the ravages of a horrific infectious disease. It is not an exaggeration to argue that in 1996 the introduction of widespread access in the US and Europe to a new class of anti-HIV drugs--the HIV protease inhibitors PI ; --although they did not offer a cure, did bring about a revolutionary breakthrough in HIV AIDS therapy. In 1995 saquinavir Invirase ; became the first HIV PI to win approval from the US Food and Drug Administration FDA ; . Soon thereafter, in 1996, the agency licensed two more PIs--ritonavir Norvir ; and indinavir Crixivan ; . Today there are 6 FDA-approved PI available by prescription in the US and a seventh fosamprenavir ; for which a New Drug Application has already been filed. With the appropriate use of the PI drugs in combination with older antiretroviral agents, it is currently possible for people living with HIV, including those with CDC-defined AIDS, to experience a significant reconstitution of their immune system, which in turn will allow many of them to enjoy relative good health for an additional 50 years and to live out a normal life span. Questions about how best to use these agents in the treatment of HIV infection and how to manage their potential toxicities and side effects have somewhat muted the recognition and appreciation of the benefits that continue to stem from this remarkable scientific and medical achievement. Like so many other aspects of HIV AIDS research, the successful use of PI therapy in HIV disease has stimulated scientific interest in their potential applications in the management of other infectious diseases and medical conditions. Research on PI use in chronic hepatitis C infection already has reached the stage of testing in humans. Several pharmaceutical and biotechnology companies have HCV PIs in various stages of development. The early promise of these drugs suggest they could offer an exciting breakthrough in HCV therapeutics that could revolutionize the treatment of that devastating viral illness in much the same way the HIV PIs have done for the treatment of HIV infection and AIDS. In addition to defining the structure of the HCV protease, researchers have discovered the structures of proteases in cytomegalovirus CMV ; , a devastating infectious disease found predominantly in people with immune-related disorders or suppression such as AIDS and organ transplant recipients, and rhinovirus, the cause of the common cold. Proteases may also affect the course of Alzheimer's disease and certain bone disorders. Since their initial introduction to the HIV treatment armamentarium almost a decade ago, clinicians, researchers and community activists have debated the timing and order of PI use with each other and in combination with anti-HIV agents from other drug classes. Initially, attention centered on concerns about the development of resistance to the HIV PIs along with discussions about the appropriate sequencing of their use as a means of slowing or halting the development of drug resistance. More recently, concerns about the PIs have focused on the potential adverse effects of these drugs. Some of their adverse side effects were noted in the clinical trials conducted prior to their marketing approval. These include gastrointestinal disturbances, such as diarrhea, nausea, and vomiting, as well as headache and abnormal laboratory findings, such as elevations in liver enzymes. Currently the major clinical concerns about the HIV PIs are their possible role in the development of lipodystrophy fat loss and fat accumulation ; , hepatotoxicity, bone disorders, hyperglycemia insulin resistance and diabetes ; , and dyslipidemia abnormally elevated triglycerides and cholesterol ; that could lead to heart disease. Debate continues about whether these outcomes are a direct result of the PI drugs alone or whether they may derive primarily from the course of HIV disease or from some combination of HIV disease progression plus anti-HIV drug effects, including not only the PIs but also anti-HIV drugs in other classes. These and other questions remain to be answered by ongoing research. It is in the context of these issues that HIV and Hepatitis has undertaken production and distribution of the "Guide to the Management of Protease Inhibitor Toxicity and Side Effects." Authored by Brian Boyle, MD, medical editor of HIV and Hepatitis and associate professor of medicine at Cornell University Medical Center, the document comprises the third in a series of three toxicity guides published by the web site on the different classes of anti-HIV drugs. Prior Toxicity Guides produced by HIV and Hepatitis in 2002 and early 2003 focused on the nucleoside tide analog reverse transcriptase inhibitors NRTI ; and the non-nucleoside reverse transcriptase inhibitors NNRTI ; classes of antiretroviral drugs. Our primary purpose in producing and distributing these Toxicity Guides is twofold. First, we believe that frank, open and scientifically rigorous discussions of the potential adverse events associated with the currently marketed anti-HIV drugs will help physicians, physician assistants, nurses, AIDS service providers, and other healthcare professionals to better understand the potential liabilities and limitations of these drugs. Armed with the scientific knowledge and clinical expertise outlined in these detailed, highly focused resources, HIV caregivers will be in a position to more ably assist patients and clients in confronting the challenges posed by these drugs' adverse effects. As a result, people living with HIV infection will enjoy an improved standard of care characterized by improved clinical outcomes and a higher quality of life. Secondly, these Toxicity Guides will serve the needs of patients by providing them with accurate, timely information that directly relates to their unique, individual situations in regard to potential drug toxicities and side effects. Improving HIV patients' knowledge of potential adverse drug effects empowers them and allows for more rapid and relevant communication with their caregivers, who as a result will be better prepared to advise them regarding the most effective and fast-acting interventions available. Corrections or clarifications to this document will be posted on the HIV and Hepatitis web site at HIVandHepatitis . Questions about clinical issues related to any of the three Toxicity Guides should be sent to medicaleditor HIVandHepatitis To receive a free copy of this Toxicity. Concomitant administration of SPORANOX with cisapride is contraindicated. See BOX WARNING, CONTRAINDICATIONS, and WARNINGS. ; Hmg CoA-Reductase Inhibitors: Human pharmacokinetic data suggest that SPORANOX inhibits the metabolism of atorvastatin, cerivastatin, lovastatin, and simvastatin, which may increase the risk of skeletal muscle toxicity, including rhabdomyolysis. Concomitant administration of SPORANOX with Hmg CoA-reductase inhibitors, such as lovastatin or simvastatin is contraindicated. See CONTRAINDICATIONS and WARNINGS. ; Immunosuppressants: Concomitant administration of SPORANOX and cyclosporine or tacrolimus has led to increased plasma concentrations of these immunosuppressants. Concomitant administration of SPORANOX and sirolimus could increase plasma concentrations of sirolimus. Macrolide Antibiotics: Erythromycin and clarithromycin are known inhibitors of CYP3A4 See Table 1 ; and may increase plasma concentrations of itraconazole. In a small pharmacokinetic study involving HIV infected patients, clarithromycin was shown to increase plasma concentrations of itraconazole. Similarly, following administration of 1 gram of erythromycin ethyl succinate and 200 mg itraconazole as single doses, the mean Cmax and AUC 0- of itraconazole increased by 44% 90% CI: 119-175% ; and 36% 90% CI: 108-171% ; , respectively. Oral Hypoglycemic Agents: Severe hypoglycemia has been reported in patients concomitantly receiving azole antifungal agents and oral hypoglycemic agents. Blood glucose concentrations should be carefully monitored when SPORANOX and oral hypoglycemic agents are coadministered. Polyenes: Prior treatment with itraconazole, like other azoles, may reduce or inhibit the activity of polyenes such as amphotericin B. However, the clinical significance of this drug effect has not been clearly defined. Protease Inhibitors: Concomitant administration of SPORANOX and protease inhibitors metabolized by CYP3A4, such as indinavir, ritonavir, and saquinavir, may increase plasma concentrations of these protease inhibitors. In addition, concomitant administration of SPORANOX and indinavir and ritonavir but not saquinavir ; may increase plasma and exelon. Through specific interactions between TRAIL and its receptors. We also showed that zVAD-fmk pancaspase inhibitor and caspase-8 inhibitor efficiently interrupted the apoptosis induced by 15d-PGJ2 and TRAIL. These observations were consistent with the characteristic features of TRAIL-induced apoptosis 33 ; . As shown in Fig. 5 bottom ; , we did Western blot analysis of apoptotic signal mediators in the same conditions with quantitative assays of apoptosis Fig. 5, top ; . DR5 up-regulation was also observed when 15d-PGJ2 was given with TRAIL. It was clearly shown that combined treatment with 15d-PGJ2 and TRAIL significantly enhanced the activation of caspase-8.
In addition to the authors, the study investigators and institutions were as follows: B. Plumstead and L. Frighetto, Vancouver General Hospital, Vancouver, B.C.; T. Noseworthy, E. Konopad, S. Bishop, M.L. Derko, and K. Horon, Royal Alexandra Hospital, Edmonton, Alta.; D. Stollery, M. Goers, and R. Jarman, Grey Nun's Hospital, Edmonton, Alta.; D. Roberts, T. Ostrusniuk, and J. Studney, Winnipeg Health Sciences Center, Winnipeg, Man.; T. Winton, D. Foster, D. Baptiste, M. Steinberg, and M. Lee, Toronto Hospital, General Division, Toronto; G. Darling, M. Culham, and V. Bobiwash, Wellesley Hospital, Toronto; M. Lefcoe study radiologist ; , D. McCormack study bronchoscopist ; , L. McCarthy, and C. Gawlik, London Health Sciences Center Victoria Campus ; , London, Ont.; S. Langdon, M. Johnson, and C. Charters, London Health Sciences Center University Campus ; , London, Ont.; M.K. Scott and S. Jansen, St. Joseph's Health Center, London, Ont.; E. McDonald, T. Dinh, and S. Toner, St. Joseph's Hospital, Hamilton, Ont.; S. Salama, Henderson Hospital, Hamilton, Ont.; A. Taite and P Newman, Kingston General Hospital, Kingston, . Ont.; M. Loewen, Ottawa Civic Hospital, Ottawa, Ont.; D. Gibbons, G. Leaman, and G. Gibbons, Health Sciences Center, St. John's, Newf.; P . Roy, M. Coffin, and H. Lummis, Victoria General Hospital, Halifax, N.S.; Methods Center -- P Austin and S. Troyan project coordinators ; , L. Buck. ingham data-base manager ; , and S. Duchesne data entry Adjudication Committees -- D. Heyland, A. Freitag, K. Gough, M. Meade, A. Sarabia, M. Turner, H. Devitt, B. Guslits, M. Heule, R. Jaeschke, and J. Lang.
Only a doctor or nurse can give you REMICADE. That means you have to go to your doctor's office or a place called an infusion center to get it. They'll hook up an IV infusion to your arm or hand and let the medicine drip in, kind of like you've seen on TV. Yeah, we know it's kind of unusual to get medicine through an IV, but there's a very good reason for it. When medicine is infused, it goes straight into your bloodstream and gets to work to help you feel better. Getting an infusion may seem weird at first, but you'll have someone nearby to make sure that everything goes well. Please read and talk to your parents and your doctor about the Medication Guide for REMICADE on pages 1522.
Life-threatening ventricular arrhythmias who are incompletely responsive to a single agent or incompletely responsive to amiodarone. During transfer to amiodarone the dose levels of previously administered agents should be reduced by 30 to 50% several days after the addition of amiodarone, when arrhythmia suppression should be beginning. The continued need for the other antiarrhythmic agent should be reviewed after the effects of amiodarone have been established, and discontinuation ordinarily should be attempted. If the treatment is continued, these patients should be particularly carefully monitored for adverse effects, especially conduction disturbances and exacerbation of tachyarrhythmias, as amiodarone is continued. In amiodarone-treated patients who require additional antiarrhythmic therapy, the initial dose of such agents should be approximately half of the usual recommended dose. Antihypertensives Amiodarone should be used with caution in patients receiving -receptor blocking agents e.g., propranolol, a CYP3A4 inhibitor ; or calcium channel antagonists e.g., verapamil, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor ; because of the possible potentiation of bradycardia, sinus arrest, and AV block; if necessary, amiodarone can continue to be used after insertion of a pacemaker in patients with severe bradycardia or sinus arrest. Anticoagulants Potentiation of warfarin-type CYP2C9 and CYP3A4 substrate ; anticoagulant response is almost always seen in patients receiving amiodarone and can result in serious or fatal bleeding. Since the concomitant administration of warfarin with amiodarone increases the prothrombin time by 100% after 3 to 4 days, the dose of the anticoagulant should be reduced by one-third to one-half, and prothrombin times should be monitored closely. Since amiodarone is a substrate for CYP3A4 and CYP2C8, drugs substances that inhibit these isoenzymes may decrease the metabolism and increase serum concentrations of amiodarone, with the potential for toxic effects. Reported examples include the following: Protease Inhibitors Protease inhibitors are known to inhibit CYP3A4 to varying degrees. Inhibition of CYP3A4 by indinavir has been reported to result in increased serum concentrations of amiodarone. Monitoring for amiodarone toxicity and serial measurement of amiodarone serum concentration during concomitant protein inhibitor therapy should be considered. Histamine H1 antagonists Loratadine, a non-sedating antihistaminic, is metabolized primarily by CYP3A4. QT interval prolongation and torsade de pointes have been reported with the coadministration of loratadine and amiodarone. Other Drugs Dextromethorphan is a substrate for both CYP2D6 and CYP3A4. Amiodarone inhibits CYP2D6.
A sample ion chromatogram is shown in Figure 1. In this example, the interfering substance s ; , which appears in the m z 316 ion track as a doublet at a relative retention time of 0.99 compared with d3-9THCA at 7.957 mm ; , is nearly separated but, at the high concentration present, it interfered with measurement of the ion ratios for d3-9THCA and thus with the quantification of the 9THCA. In procedures with much slower retention time and poorer resolution, the substance s ; caused even greater interference, and its presence often could not be distinguished chromatographically. To separate the substance from 9THCA, we used a modified chromatographic procedure and identified it as a metabolite of ritodrine, a beta-blocking drug prescribed to prevent prema and buy aricept.
ACKNOWLEDGEMENT We thank Professor Don Birkett for his comments on an earlier draft of this article. NOTE For a table of drugs metabolised by cytochrome P450 see : drug-interactions REFERENCES 1. Dresser GK, Spence JD, Bailey DG. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 2000; 38: 41-57. Wilbur K, Ensom MH. Pharmacokinetic drug interactions between oral contraceptives and second-generation anticonvulsants. Clin Pharmacokinet 2000; 38: 355-65. Drug interactions and adverse drug reactions. Aust Adv Drug React Bull 2000; 19: 10-2. Piscitelli SC, Burstein AH, Chaitt D, Alfaro RM, Falloon J. Indinavir concentrations and St John's wort [letter]. Lancet 2000; 355: 547-8. Bailey DG, Malcolm J, Arnold O, Spence JD. Grapefruit juice-drug interactions. Br J Clin Pharmacol 1998; 46: 101-10. Josefsson M, Zackrisson AL, Ahlner J. Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers. Eur J Clin Pharmacol 1996; 51: 189-93. Shenfield GM, Page M. Potentiation of warfarin action by miconazole oral gel [letter]. Aust N Z J Med 1991; 21: 928. Edgar B, Bailey D, Bergstrand R, Johnsson G, Regardh CG. Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics of felodipine and its potential clinical relevance. Eur J Clin Pharmacol 1992; 42: 313-7. Kivisto KT, Kroemer HK, Eichelbaum M. The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions. Br J Clin Pharmacol 1995; 40: 523-30. Kent JM. SNaRIs, NaSSAs, and NaRIs: new agents for the treatment of depression [published erratum appears in Lancet 2000; 355: 2000]. Lancet 2000; 355: 911-8.
High levels of BNP, measured in pg ml, helped to determine the correct diagnosis in approximately 83% of the patients in the study at a cutoff of 100 pg ml. 0-100 pg ml is considered "within normal limits" ; . Plasma BNP may also be useful as a prognostic tool and guide to therapy when measured at initial presentation. Markedly high BNP concentrations initially can identify patients at high risk for sudden cardiac death. In patients with chronic heart failure, therapy may be guided by BNP concentration. The BNP should fall when the condition improves and rise when condition worsens. Persistently elevated plasma BNP would be significant in prognosis. The use of BNP should be recommended in patients with dyspnea of unknown etiology, including patients with heart failure and those with non-cardiac causes of dyspnea. Plasma BNP should also be used to monitor for exacerbation in patients diagnosed with heart failure. Lastly, plasma BNP should be used to assess efficacy of current therapies, evident by a decrease from baseline. One point to remember when considering use of this test is to adjust cutoffs for age and gender due to higher natural concentrations. Also, a high BNP does not exclude other diseases that may contribute to dyspnea. Plasma BNP should not be used in place of clinical judgment, but as an adjunct to clinical judgment. In patients with severe disease, BNP may remain elevated and not decrease with treatment, therefore may not be used to measure response to therapy in these patients. In summary, high plasma BNP concentrations are reflective of left ventricular dysfunction and may be used as a diagnostic tool for heart failure in patients with dyspnea of unknown origin. BNP is approved by the FDA to be used as diagnostic marker for heart failure and should be used in conjunction with clinical judgment. Article by Emily Roddy, PharmD Candidate, UNC-Chapel Hill School of Pharmacy.
Indinavir sulphate capsules
Indinavif, imdinavir, indinavlr, incinavir, indinair, indinqvir, indinnavir, indinavit, jndinavir, insinavir, indiinavir, indinwvir, indimavir, indinacir, infinavir, ibdinavir, indinavor, indinavi5, kndinavir, indinavvir, indinavie, indinavkr, indinvair, ndinavir, indunavir, indianvir, ihdinavir, indinavur, ind8navir, inddinavir, indinaavir, indinavid, indlnavir, indinav9r, ind9navir, ondinavir, idninavir, indinagir.Canadian Indinavir
Can indinavir affect human cells, discount indinavir online, indinavir antiretroviral, indinavir sulphate capsules and canadian indinavir. Indinavir information, indinavir medicine, indinavir tdm and discount generic indinavir online or indinavir dosis.
Indinavir information
Doxazosin mesilate, transcranial magnetic stimulation depression, backbone upgrade, adrenal cortex by allergy research group and adenosine thallium scan definition. Bed bug varieties, senescence assay, cotinine urinalysis and sprained ankle delayed pain or aging fast.